logo-loader
Bioasis Technologies Inc.

Full interview: Bioasis Technologies new CEO says favorable response from FDA on its xB3 therapy 'encouraging'

Bioasis Technologies Inc (OTCQB:BIOAF) (TSX.V:BTI) CEO Dr. Deborah Rathjen tells Proactive the pre-clinical biopharma group has received positive feedback from the FDA on its pre-investigational new drug (IND) application for its xB3-001 therapy for the treatment of patients with a type of breast cancer and brain metastases. Rathjen says the FDA's favorable feedback included a suggestion the company might consider the next steps of the drug development process towards entering Phase 1 trials.

Quick facts: Bioasis Technologies Inc.

Price: $0.22

Market: OTCMKTS
Market Cap: $13.9 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Rockfire Resources' David Price discusses Brigalow Alluvial...

Rockfire Resources PLC's (LON:ROCK) David Price tells Proactive London's Andrew Scott they've been getting a better understanding of an alluvial gold deposit next one of their main assets in Queensland. Calculations made in 1986 on an area known as Brigalow Alluvial Goldfield has suggested...

2 days, 18 hours ago

2 min read